In this study, we investigate the MDM2 polymorphisms SNP309, SNP285 and del1518 for potential impact on hematopoietic recovery, focusing on neutrophil counts during neoadjuvant chemotherapy treatment with sequential monotherapy of epirubicin and docetaxel in patients with primary breast cancer. Here, MDM2 is linked to breast carcinoma.